Mary Jones, APRN
Family · Fayetteville, ARNPI 1265460430
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $709 of the $961 with a category attached, or 73.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 17.4%.
Across 39 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$168
- Pharmaessentia USA Corporation$121
- Incyte Corporation$100
- Seagen Inc.$74
- Merck$74
- Johnson & Johnson$64
- plus $360 from 13 others
What the payments were for
- Food & beverage$70974%
- Education$25226%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 2 | $168 |
| Pharmaessentia USA Corporation | 1 | $121 |
| Incyte Corporation | 1 | $100 |
| Seagen Inc. | 1 | $74 |
| Merck | 5 | $74 |
| Johnson & Johnson(2 entities) | 3 | $64 |
| Sanofi | 4 | $52 |
| Bristol Myers Squibb | 3 | $49 |
| Tersera Therapeutics LLC | 3 | $39 |
| Eisai Inc. | 3 | $39 |
| Amgen | 1 | $37 |
| AbbVie | 2 | $28 |
| Daiichi Sankyo Inc. | 2 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Iovance Biotherapeutics, Inc. | 1 | $14 |
| Genmab U.S., Inc. | 1 | $14 |
| Myovant Sciences Inc. | 1 | $13 |
| Genentech USA, Inc. | 3 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BESREMI$121
How this compares
$961 in reported general payments places this provider in the 65th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 11 | $107 |
Paid to pharmacies, not to this prescriber.
Other family in Fayetteville
- Shelby CochranFayetteville$23K
- Margaret OliverFayetteville$12K
- Christopher TitsworthFayetteville$9K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.